Aquatic Capital Management LLC Buys New Position in Perspective Therapeutics, Inc. (NYSE:CATX)

Aquatic Capital Management LLC bought a new position in Perspective Therapeutics, Inc. (NYSE:CATX) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 32,718 shares of the company’s stock, valued at approximately $104,000.

Several other institutional investors have also recently added to or reduced their stakes in CATX. Virtus ETF Advisers LLC increased its stake in shares of Perspective Therapeutics by 157.9% in the 4th quarter. Virtus ETF Advisers LLC now owns 20,487 shares of the company’s stock valued at $65,000 after acquiring an additional 12,542 shares in the last quarter. Nebula Research & Development LLC grew its holdings in Perspective Therapeutics by 47.2% in the fourth quarter. Nebula Research & Development LLC now owns 21,850 shares of the company’s stock worth $70,000 after purchasing an additional 7,007 shares during the period. Rock Springs Capital Management LP increased its stake in Perspective Therapeutics by 7.2% in the fourth quarter. Rock Springs Capital Management LP now owns 444,383 shares of the company’s stock valued at $1,418,000 after purchasing an additional 29,987 shares in the last quarter. Affinity Asset Advisors LLC raised its holdings in shares of Perspective Therapeutics by 160.0% during the fourth quarter. Affinity Asset Advisors LLC now owns 1,300,000 shares of the company’s stock valued at $4,147,000 after purchasing an additional 800,000 shares during the period. Finally, Jump Financial LLC bought a new position in shares of Perspective Therapeutics during the 4th quarter worth about $688,000. 54.66% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Wedbush reaffirmed an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a research note on Wednesday, March 26th. Lifesci Capital upgraded Perspective Therapeutics to a “strong-buy” rating in a report on Thursday, March 6th. Royal Bank of Canada dropped their price objective on shares of Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating on the stock in a research note on Thursday, March 27th. Cantor Fitzgerald raised Perspective Therapeutics to a “strong-buy” rating in a research note on Tuesday, March 4th. Finally, Truist Financial cut their target price on Perspective Therapeutics from $21.00 to $10.00 and set a “buy” rating on the stock in a research report on Monday, April 7th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $12.75.

Insider Transactions at Perspective Therapeutics

In other Perspective Therapeutics news, CFO Juan Graham acquired 33,333 shares of the business’s stock in a transaction that occurred on Friday, March 28th. The stock was bought at an average cost of $2.25 per share, with a total value of $74,999.25. Following the acquisition, the chief financial officer now owns 35,354 shares in the company, valued at approximately $79,546.50. This represents a 1,649.33 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Johan M. Spoor acquired 22,026 shares of Perspective Therapeutics stock in a transaction that occurred on Friday, March 28th. The stock was acquired at an average price of $2.24 per share, with a total value of $49,338.24. Following the completion of the purchase, the chief executive officer now directly owns 59,383 shares in the company, valued at $133,017.92. This represents a 58.96 % increase in their position. The disclosure for this purchase can be found here. Insiders purchased a total of 115,696 shares of company stock worth $256,344 in the last quarter. Insiders own 3.52% of the company’s stock.

Perspective Therapeutics Stock Performance

NYSE CATX opened at $2.43 on Tuesday. Perspective Therapeutics, Inc. has a 52-week low of $1.60 and a 52-week high of $19.05. The company has a 50-day simple moving average of $2.27 and a 200 day simple moving average of $4.19.

Perspective Therapeutics Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.